Literature DB >> 33311787

Review of Rapid Advances in Cystic Fibrosis.

Stephanie L Link1, Ravi P Nayak2.   

Abstract

Cystic fibrosis (CF) is an autosomal recessive disease that was previously a fatal pediatric disease with no treatment; however, due to scientific advancements, the median age of survival for the CF population born in 2018 has increased from 29 in 1989 to 47.4 in 2018. This is an innovative era for the treatment of CF as advanced research continues to evolve and novel treatments for the disease and related illnesses are discovered. Copyright 2020 by the Missouri State Medical Association.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33311787      PMCID： PMC7721430     

Source DB:  PubMed          Journal:  Mo Med        ISSN： 0026-6620


  26 in total

1.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Authors:  Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

2.  Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.

Authors:  Jennifer L Taylor-Cousar; Anne Munck; Edward F McKone; Cornelis K van der Ent; Alexander Moeller; Christopher Simard; Linda T Wang; Edward P Ingenito; Charlotte McKee; Yimeng Lu; Julie Lekstrom-Himes; J Stuart Elborn
Journal:  N Engl J Med       Date:  2017-11-03       Impact factor: 91.245

Review 3.  The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis.

Authors:  J Paccou; N Zeboulon; C Combescure; L Gossec; B Cortet
Journal:  Calcif Tissue Int       Date:  2009-12-01       Impact factor: 4.333

Review 4.  Cystic fibrosis.

Authors:  Felix Ratjen; Scott C Bell; Steven M Rowe; Christopher H Goss; Alexandra L Quittner; Andrew Bush
Journal:  Nat Rev Dis Primers       Date:  2015-05-14       Impact factor: 52.329

5.  Cystic fibrosis pulmonary guidelines: airway clearance therapies.

Authors:  Patrick A Flume; Karen A Robinson; Brian P O'Sullivan; Jonathan D Finder; Robert L Vender; Donna-Beth Willey-Courand; Terry B White; Bruce C Marshall
Journal:  Respir Care       Date:  2009-04       Impact factor: 2.258

Review 6.  Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.

Authors:  Marcus A Mall; Nicole Mayer-Hamblett; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

Review 7.  Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.

Authors:  Patrick A Flume; Peter J Mogayzel; Karen A Robinson; Christopher H Goss; Randall L Rosenblatt; Robert J Kuhn; Bruce C Marshall
Journal:  Am J Respir Crit Care Med       Date:  2009-09-03       Impact factor: 21.405

Review 8.  Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.

Authors:  G J Connett
Journal:  Drug Des Devel Ther       Date:  2019-07-19       Impact factor: 4.162

Review 9.  Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis.

Authors:  Cecilia Velino; Francesca Carella; Alessio Adamiano; Maurizio Sanguinetti; Alberto Vitali; Daniele Catalucci; Francesca Bugli; Michele Iafisco
Journal:  Front Bioeng Biotechnol       Date:  2019-12-17

10.  Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality.

Authors:  Antoinette Moran; Jordan Dunitz; Brandon Nathan; Asad Saeed; Bonnie Holme; William Thomas
Journal:  Diabetes Care       Date:  2009-06-19       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.